Videos

Judd W. Moul, MD, FACS, wraps up by discussing remaining unmet needs and potential future improvements in imaging modalities for prostate cancer screening.

An expert urologic oncologist revisits a patient profile and discusses how he would have approached the patient’s prostate cancer screening process.

Judd W. Moul, MD, FACS, gives a real-world overview of how the exosome-based test is used in clinical practice.

An overview of the clinical validity and utility of a urine-based, exosomal molecular test for prostate cancer screening and risk assessment.

Judd W. Moul, MD, FACS, provides insight into the timing of biomarker testing in the prostate cancer screening process, and discusses which patients might benefit the most from testing.

Judd W. Moul, MD, FACS, introduces available blood- and urine-based biomarker tests for prostate cancer screening, and discusses how they might overcome limitations of commonly used modalities.

A focused discussion on the use of tools such as digital rectal exam, prostate biopsy, and MRI in prostate cancer diagnosis, staging, and grading.

Judd W. Moul, MD, FACS, reviews challenges of early detection of prostate cancer, and strategies to mitigate them.

A commentary on increasing trends in prostate cancer incidence and how many patients typically present with severe disease.

Judd W. Moul, MD, FACS, introduces the patient profile and discusses typical characteristics of patients undergoing prostate cancer screening in his practice.

“We…just need to apply operational efficiencies that are utilized in other industries [to] health care,” says Shirley Lee, CRNP-FNP, MPH.

“Status quo EHR [and] status quo documenting [are] not going to give us the insights that we really need about how [patients are] doing now, and what are the opportunities we have to improve their care,” says Shirley Lee, CRNP-FNP, MPH.

“Clinically speaking, it really can harm patients to have gaps in both the data and their care,” says Shirley Lee, CRNP-FNP, MPH.

A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.

Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.

"I would say our greatest advance of the past 30 years is our clinical trials infrastructure, because we can now use our therapies with intelligence," says Anthony Zietman, MD.

Authors from the OSPREY clinical trial highlight the key take-home messages from the trial outcomes.

Key opinion leaders review the OSPREY clinical trial studying PSMA PET scans for prostate cancer imaging.

“Overall, there's no known advantage or disadvantage in a head-to-head trial of either one of these, but I do think they're complementary,” says Scott T. Tagawa, MD, when discussing radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan.

“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.

“I think we are good at treating the cancer but maybe not great at treating the patient as a whole. And that is an area that we can improve going forward based on research like this,” says Amy N. Luckenbaugh, MD.

In this conversation, Acacia Brush Perko, Esq, and Kenton H. Steele, Esq, discuss the qualities that comprise a good expert witness in a malpractice lawsuit.

“We kind of expected that treatment type wouldn't make a ton of difference in terms of…mental health outcomes after either surgery or radiation…but we were very clearly able to find groups of people who were at risk for poor mental health outcomes,” says Amy N. Luckenbaugh, MD.

“Oral tebipenem pivoxil hydrobromide and intravenous ertapenem had a similar safety and tolerability profile,” says Angela Talley, MD.

“I think it's important to look at our practice from the consumer standpoint and see what we look like to our patients,” says Polina X. Reyblat, MD.

"Peyronie's disease has really seen a wide range of intralesional options through the years," says Denise Asafu-Adjei, MD, MPH.

“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.

“The take-home message is that there is a new form of lithotripsy,” says Jonathan D. Harper, MD.

“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.

“Patients need to understand that even if you tell them that you may be doing this as an ambulatory procedure, they may actually have to stay afterwards, depending on what you find in the operating room or what happens in the postoperative period,” says Michael A. Palese, MD.